Capricor Therapeutics (FRA:4LN2) Defensive Interval Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4LN2 Capricor Therapeutics Inc FRA:4LN2
37 GF Score
Price €7.81
GF Value €4.03
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Capricor Therapeutics Defensive Interval Ratio?

FRA:4LN2
37GF Score
Capricor Therapeutics Inc FRA:4LN2
Defensive Interval Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Capricor Therapeutics (FRA:4LN2) Overvalued in 2026?

Based on GuruFocus' analysis, Capricor Therapeutics stock appears to be overvalued. The current stock price of €7.81 is trading 93.9% above its estimated GF Value™ of €4.03. GuruFocus considers Capricor Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:4LN2:

  • Defensive Interval Ratio:
  • GF Value™: €4.03 vs. price of €7.81 (93.9% above fair value)
  • GF Score™: 37/100 with 3 warning signs

No single metric tells the full story. See the FRA:4LN2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Capricor Therapeutics Business Description

Other Exchanges CAPR:USA4LN2:Germany
Address 10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121
Capricor Therapeutics Inc is a clinical-stage biotechnology company based in the United States that develops cell and exosome-based therapeutics for rare diseases. Its lead candidate, deramiocel (CAP-1002), is an allogeneic cardiac-derived cell therapy in late-stage clinical development for Duchenne muscular dystrophy, a rare genetic disorder causing progressive muscle degeneration. The company also operates its StealthX exosome platform, which is used in preclinical research for vaccine development and the delivery of oligonucleotides, proteins, and small molecules. Capricor's efforts target diseases with high unmet medical need, particularly neuromuscular and cardiac conditions. As a clinical-stage company, it does not yet generate product revenue; funding comes primarily from equity financings, research grants, and partnership arrangements, including a collaboration with Nippon Shinyaku for the development and commercialization of deramiocel in Japan.
37GF Score

Get the complete analysis for FRA:4LN2

Defensive Interval Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.81
Price
€4.03
GF Value